Approval · Notice of Compliance 26512 · 2021
VOTRIENT: Notice of Compliance 26512
Issued August 25, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26512
- Date
- August 25, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety update to the Product Monograph; Removal of the 400 mg strength; and Convert the Product Monograph to the 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VOTRIENT | Not yet assigned | — |
Medicinal ingredients
- PAZOPANIB HYDROCHLORIDE 200 MG per TAB
- PAZOPANIB HYDROCHLORIDE 400 MG per TAB